Amgen Inc. (AMGN)
NASDAQ · Healthcare · Drug Manufacturers - General
Profile
Amgen Inc.
- Exchange
- NASDAQ
- Ticker
- AMGN
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- US
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.
Key facts
Amgen Inc.: key facts
- Amgen Inc. (NASDAQ: AMGN) is a Drug Manufacturers - General company in the Healthcare sector.
- In fiscal 2025, Amgen Inc. reported revenue of $36.7B and net income of $7.7B.
- Revenue grew 9.1% a year over the last 4 fiscal years.
- Free cash flow was positive in 5 of the last 5 fiscal years.
- Net income was positive in 5 of the last 5 fiscal years.
- Over the last twelve months, revenue was $38.1B and net income was $8.7B.
MonkScore
Amgen Inc.'s MonkScore
MonkScore
MonkScore range: 90–100
as of October 2026
Sector rank: 65 of 628 in Healthcare
How this score is madeDisclaimer
Pillar ranges
- Growth90–100
- Profitability70–80
- Quality60–70
- Market Conviction90–100
- Safety70–80
The MonkScore runs from 0 to 100. Each range is one of ten 10-point groups, from 0–10 to 90–100.
Each pillar's range uses the same ten groups. The exact score and the pillar scores are in the MonkStreet app.
Fundamentals
Figures from the statements
Amgen Inc.'s annual figures and the last twelve months, in USD. Last report: 30 June 2026.
| Figure | Last 12 months | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Revenue | $38.1B | $36.7B | $33.4B | $28.2B | $26.3B | $26.0B |
| Gross profit | $27.7B | $26.0B | $20.6B | $19.8B | $19.9B | $19.5B |
| Operating income | $12.6B | $10.7B | $7.3B | $7.9B | $9.6B | $7.6B |
| Net income | $8.7B | $7.7B | $4.1B | $6.7B | $6.6B | $5.9B |
| Operating cash flow | $12.5B | $10.0B | $11.5B | $8.5B | $9.7B | $9.3B |
| Capital expenditure | -$2.3B | -$1.9B | -$1.1B | -$1.1B | -$936.0M | -$880.0M |
| Free cash flow | $10.2B | $8.1B | $10.4B | $7.4B | $8.8B | $8.4B |
| Total debt | $57.3B | $54.6B | $60.1B | $64.6B | $38.9B | $33.3B |
| Cash | $14.0B | $9.1B | $12.0B | $10.9B | $7.6B | $8.0B |
Revenue growth a year
- 1-year
- 9.9%
- 3-year
- 11.8%
- 4-year
- 9.1%
Compound growth between fiscal years.
Peers
Similar companies
- AbbVie Inc.NYSE:ABBVMonkScore range: 90–100
- Gilead Sciences, Inc.NASDAQ:GILDMonkScore range: 90–100
- Eli Lilly and CompanyNYSE:LLYMonkScore range: 90–100
Score my top stocks · 14-day free trial · card required · not charged during the trial · cancel in one click
MonkStreet provides research, not investment advice.
Page built on 31 October 2026.